Drug Patent Suits' Novel Theory Tests False Claims Act Limits

January 2022

Partner Ben Greenblum and associates Arthur Argall and Patrick Bradley co-authored the article “Drug Patent Suits' Novel Theory Tests False Claims Act Limits” published by Law360. The article explores noteworthy False Claims Act matters that rely on information disclosed in federal patent proceedings, including inter partes review, to make claims that patentholders defrauded the government by inflating drug prices based on invalid patents that delayed generic competition. 

Click here to read the full article. 

back to top